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Abstract 
Long interspersed element‑1 (LINE‑1/L1) is the only autonomous transposable element in the human genome that 
currently mobilises in both germline and somatic tissues. Recent studies have identified correlations between altered 
retrotransposon expression and the fatal neurodegenerative disease amyotrophic lateral sclerosis (ALS) in a subset of 
patients. The risk of an individual developing ALS is dependent on an interaction of genetic variants and subsequent 
modifiers during life. These modifiers could include environmental factors, which can lead to epigenetic and genomic 
changes, such as somatic mutations, occurring in the neuronal cells that degenerate as the disease develops. There 
are more than 1 million L1 copies in the human genome today, but only 80–100 L1 loci in the reference genome 
are considered to be retrotransposition‑competent (RC) and an even smaller number of these RC‑L1s loci are highly 
active. We hypothesise that RC‑L1s could affect normal cellular function through their mutagenic potential conferred 
by their ability to retrotranspose in neuronal cells and through DNA damage caused by the endonuclease activity of 
the L1‑encoded ORF2 protein. To investigate whether either an increase in the genomic burden of RC‑L1s or epige‑
netic changes to RC‑L1s altering their expression, could play a role in disease development, we chose a set of seven 
well characterised genomic RC‑L1 loci that were reported earlier to be highly active in a cellular L1 retrotransposition 
reporter assay or serve as major source elements for germline and/or somatic retrotransposition events. Analysis of 
the insertion allele frequency of five polymorphic RC‑L1s, out of the set of seven, for their presence or absence, did 
not identify an increased number individually or when combined in individuals with the disease. However, we did 
identify reduced levels of methylation of RC‑L1s in the motor cortex of those individuals with both familial and spo‑
radic ALS compared to control brains. The changes to the regulation of the loci encompassing these RC‑L1s demon‑
strated tissue specificity and could be related to the disease process.
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Introduction
Long interspersed element-1 (LINE-1/L1) represents the 
only autonomous retrotransposon family in the human 
genome whose members are currently mobilised and it 
constitutes a significant source of endogenous mutagen-
esis [1]. L1 elements are non-long terminal repeat (non-
LTR) retrotransposons, which propagate through a ‘copy 
and paste’ mechanism including L1 cDNA synthesis 
by a process termed target primed reverse transcrip-
tion [2, 3]. A functional, full length L1 element is ~ 6 kb 
in length, contains both a 5′ and 3′-untranslated region 
(UTR), three open reading frames (ORF0, ORF1, ORF2) 
and a poly A tail at its 3′end, and is flanked by variable 
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target site duplications. ORF1p, a ~ 40 kDa protein with 
RNA binding and chaperone activities, and ORF2p, 
a ~ 150 kDa protein with endonuclease and reverse tran-
scriptase activities, are essential for L1 retrotransposition 
[4–7]. L1 sequences contribute to approximately 17% of 
the human genome with over one million copies, how-
ever, by far the majority are unable to mobilise due to 
5′-truncations, internal deletions or rearrangements and 
mutations in the ORFs encoding the proteins required 
for retrotransposition [8, 9]. The GRCh38 release of the 
human genome contains 146 full-length L1 elements 
harbouring intact open reading frames (ORFs) [10]. It is 
estimated there are approximately 80–100 retrotranspo-
sition competent L1 loci (RC-L1) in the average human 
genome, however testing these elements in retrotranspo-
sition reporter assays in cell culture revealed that there 
are only six highly active or ‘hot’ L1 elements in the ref-
erence genome that were responsible for the majority 
of  retrotransposition activity measured [11]. Approxi-
mately 15% of all L1 retrotransposition events in the 
human genome result in the transduction of 3′ flanking 
genomic sequences as the L1 encoded canonical polyade-
nylation signal is bypassed by RNA-Polymerase II allow-
ing the new L1 insertions to be traced back to their source 
locus [12, 13]. This has identified highly active genomic 
RC-L1 loci that are responsible for many new insertions 
in the germline, in somatic cells or both [14–17]. In addi-
tion, many of these highly active RC-L1s are polymorphic 
for their presence or absence in the genome, therefore 
every individual has a different complement of RC-L1 
loci, which could result in distinct amounts of functional 
L1 mRNA.
L1 retrotransposition is repressed by multiple cellular 
mechanisms including the methylation of a CpG island 
located in the 5′UTR acting to reduce the levels of L1 
mRNA expressed [18–21]. However, L1 retrotransposi-
tion does occur in the developing embryo and in germ, 
tumour and neuronal cells generating either heritable 
insertions or somatic insertions that are present in only 
a specific cellular lineage or even a single cell [21–24]. 
The extent to which these new L1 insertions affect func-
tion will depend on their genomic integration sites and 
will range from loss of function mutations (when inser-
tions disrupt exons) to changes in transcript levels of an 
expressed gene [25]. L1 insertions in both germ cells and 
embryonic stem cells have been shown to be the cause 
of genetic disease and the somatic retrotransposition of 
a particularly active RC-L1 copy into the APC gene ini-
tiated a case of colorectal cancer [26–28]. Somatic L1 
retrotransposition occurs in the human brain with rates 
reported ranging from 0.04 to 13.7 L1 insertions per neu-
ron, although there is much debate on the actual mobili-
sation frequency in this cell type [29]. It is hypothesised 
that a controlled level of somatic retrotransposition in 
neuronal genomes may contribute to neuronal plasticity 
however beyond a beneficial level it could be involved in 
neurodegeneration and disease [30].
Amyotrophic lateral sclerosis (ALS) is a neurodegen-
erative disease with an uncertain aetiology involving the 
rapid and progressive degeneration of motor neurons 
of the brain and spinal cord. It is usually fatal within 
3–5 years of disease onset and there are no current treat-
ments to reverse or stop the course of the disease [31]. 
ALS cases are often divided into those with a family his-
tory of the disease (familial, FALS) and those without 
(sporadic, SALS). ALS is thought to represent one end 
of a spectrum disorder with frontotemporal dementia 
(FTD) at the other end due to significant overlap of the 
genetics and altered cellular pathways involved in both 
diseases [32]. Protein aggregates of TAR DNA binding 
protein (TDP-43) are a hallmark of the majority of ALS 
cases and 45–60% of FTD cases and multiple studies 
have demonstrated that retrotransposons, including L1, 
are regulated by TDP-43 [33–35]. Several studies have 
also shown correlations between altered retrotransposon 
expression and ALS and FTD when comparing expres-
sion in the brain of individuals with and without disease 
and in animal models [36–40]. A recent study using post-
mortem cortex samples identified three distinct subsets 
of ALS patients one of which was characterised by de-
silencing of multiple families of transposable elements 
that can be assigned to the groups of both LTR and non-
LTR retrotransposons (including L1) and associated with 
TDP-43 dysfunction (20% of patients) [36]. In other stud-
ies, retrotransposon expression was significantly altered 
in ALS patients who were positive for the hexanucleotide 
repeat expansion in the C9orf72 gene but not in those 
who were negative for the expansion [39, 40]. In rodent 
and Drosophila models of TDP-43 pathology, TDP-43 
represses non-LTR and LTR retrotransposon transcripts 
[37, 38]. Moreover a reduction in the binding of TDP-43 
to retrotransposon transcripts was observed in the brains 
of FTD patients compared to controls [38]. The loss of 
nuclear TDP-43 in brain tissue from FTD-ALS patients 
has been associated with decondensation of chroma-
tin flanking L1 loci and an increase in L1 DNA content 
[41]. In addition, a cellular model of TDP-43 loss resulted 
in an increase in L1 retrotransposition, which could be 
inhibited by antiretroviral drugs [41].
We hypothesise that either an increase in the genomic 
burden of RC-L1s could contribute to the genetic risk of 
an individual to ALS or epigenetic changes to these L1 
loci altering their expression or both could play a role in 
disease development. To address these hypotheses, we 
generated a list of seven genomic RC-L1 loci (Table  1) 
that were reported to exhibit high retrotransposition 
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frequencies in L1 retrotransposition reporter assays or 
were a source of a high number of L1 insertions in either 
the germline, somatic tissues or both to be the focus of 
this study [11, 14, 15, 17, 42]. Genotyping of specific pol-
ymorphic RC-L1 loci was performed on samples from the 
MNDA UK (Motor Neurone Disease Association United 
Kingdom) DNA bank cohort [43] and the UK Project 
MinE samples using PCR and tagging single nucleotide 
polymorphisms (SNPs), respectively [44, 45]. Genotypes 
of tagging SNPs served as a proxy for the specific RC-L1 
genotype. In order to assess the relative methylation sta-
tus of the specific RC-L1 loci shortlisted, we enriched 
methylated gDNA employing a methyl-binding domain 
(MBD) protein to produce methylated and unmethylated 
DNA fractions from cerebellum, motor cortex and blood 
of healthy controls and individuals with FALS and SALS. 
Genotyping of these selected RC-L1 insertions did not 
reveal any association with disease risk or an increased 
burden of their presence in individuals with ALS in the 
cohorts used in this study. However, methylation analy-
sis of these elements in the brain identified a higher level 
of methylation in control individuals compared to those 




Genomic DNA (gDNA) samples for genotyping of the 
five specific polymorphic RC-L1 insertions were obtained 
from the MNDA UK DNA bank cohort (ref DNA0042). 
gDNA of 2 control, 2 familial ALS and 2 sporadic ALS 
cases was obtained from the cerebellum and motor cor-
tex from the London Neurodegenerative Diseases Brain 
Bank. Of the two FALS cases one carried the SOD1 
p.D101G variant and the other the TARDBP p.M337V 
variant. The 3 sporadic ALS gDNA samples from the 
blood and motor cortex were obtained from the Shef-
field Brain Tissue bank. Sample details are summarised in 
Additional file 1.
Genotyping of five polymorphic RC‑L1 loci in the MNDA UK 
DNA bank and UK Project MinE cohorts
The five selected polymorphic RC-L1 insertions were 
genotyped in gDNA samples from the MNDA UK DNA 
bank cohort, London Neurodegenerative Diseases Brain 
Bank and Sheffield Brain Tissue bank using GoTaq hot 
start polymerase (Promega) under standard condi-
tions. PCR assays to test for presence/absence of each 
RC-L1 locus were designed with three primers each, two 
flanking the insertion and one located in the L1 5′ UTR 
(5′AAC TCC CTG ACC CCT TGC 3′; position 206–223 of 
the benchmark L1.3 element (accession no: L19088.1) 
[46], enabling amplification of the empty site and/or the 
L1 5′ junction within the same reaction (Fig. 2d). For two 
of the RC-L1 loci this PCR design was not appropriate 
due to differences in conditions required for each primer 
set. Therefore two PCR reactions were carried out, one 
for the empty site and another for the L1 5′ junction. 
Primer sequences are listed in Additional file  2. DNA 
samples in the MNDA UK DNA bank cohort have been 
Table 1 Retrotransposition competent L1 elements chosen for genotyping and methylation analysis in ALS cohort
The RC-L1 elements were shortlisted based on their high level of activity in a cellular retrotransposition assay [11, 14, 42], high number of germline offspring elements 
from 3′ transductions analysis [15] or high number of somatic insertions in cancer from 3′ transductions analysis [17]. Non-ref RIP: L1s that are not in the human 
reference genome and are polymorphic for their presence/absence. Ref RIP: L1s that are present in the human reference genome and are polymorphic for their 
presence/absence. Ref: L1s present in the human reference genome and there is currently no evidence that they are polymorphic for their presence/absence
Name Percentage 
of retrotransposition 
activity of L1RP [11, 
14, 42]












L1_chr2_q24.1 150 Non‑ref RIP na,0.16 41/121 21/655 chr2:156,527,848
intergenic
L1_chr6_q24.1 141 Non‑ref RIP na,0.18 14/121 98/655 chr6:13,191,033
Intron PHACTR1
L1_chrX_p22.2 132 Ref RIP 0.34,0.74 1/121 20/655 chrX:11,953,208
intergenic
L1_chr6_p22.3 112.7 Ref RIP 0.30,0.61 2/121 2/655 chr6:24,811,907
Intron FAM65B
L1_chr8_q24.22 89.4 Ref RIP 0.44,1 2/121 4/655 chr8:135,082,987
intergenic
L1_chr1_p12 – Ref 1,1 13/121 7/655 chr1:119,394,974
intergenic
L1_chr22_q12.1 13.8 Ref 1,1 2/121 137/655 chr22:29,059,272
Intron TTC28
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sequenced as part of Project MinE. Therefore, SNP geno-
type data was available and the genotypes of candidate 
tagging SNPs for each of the polymorphic RC-L1s were 
obtained. Linkage disequilibrium (LD) between the SNPs 
and RC-L1 loci for those samples that both genotypes 
were available for, was calculated using PLINK (v1.07) 
[47]. The genotypes of the five polymorphic RC-L1 loci 
were then determined by the genotypes of the proxy 
SNPs in the Project MinE UK samples. Association anal-
ysis of the RC-L1 insertions and ALS was carried out 
using a Chi-squared test (PLINK v1.07). Two-sample test 
for equality of proportions with continuity correction 
combined with Chi-squared test was used to evaluate 
the proportions of insertion numbers of RC-L1 between 
cases and controls. Logistic regression was performed to 
determine if the total number of RC-L1s present at the 5 
polymorphic loci were associated with disease status.
Isolation of methylated and unmethylated DNA
Genomic DNA (gDNA) from controls, familial and spo-
radic ALS patients was sheared using a S220 focused-
ultrasonicator (Covaris) with the following parameters 
duty cycle 5%, intensity 3 and cycles per burst 200 for 
40 s × 4 to obtain fragments of 500 bp. The sheared gDNA 
was then purified and concentrated using a 1:1.1 ratio 
of DNA to Agencourt AMPure XP Beads (Beckman 
Coulter). Methylated and unmethylated DNA was iso-
lated from 300 ng of each gDNA sample using the CpG 
MethylQuest kit (Millipore) according to manufacturer’s 
instructions. The CpG island of SNRPN, an imprinted 
locus, was used as positive control for the successful 
enrichment of gDNA in both methylated and unmethyl-
ated fractions and to determine if there was relative equal 
representation of methylated and unmethylated alleles in 
the respective fractions of gDNA. The volume of isolated 
gDNA from the methylated and unmethylated fractions 
that yielded equal signal intensities in the PCR for the 
SNRPN locus was used as input for the amplification of 
the 5′ junction of the RC-L1s and the empty sites.
Quantification of the methylation status of CpG islands 
of selected RC‑L1 loci
The 5′ junctions of 6 RC-L1 loci from Table 1 (except L1_
chr2_q24.1) and the SNRPN locus were amplified in the 
methylated and unmethylated fractions of gDNA using 
primers in Additional file  2 and GoTaq hot start poly-
merase (Promega) under standard conditions. L1_chr2_
q24.1 could not be amplified in the fragmented gDNA, 
as a large PCR product (985 bp) was required due to the 
presence of the highly repetitive region in which the L1 
has inserted. Not including L1_chr2_q24.1 the length 
of flanking nucelotide sequence included in the PCR 
product of the RC-L1 5′ junction was 158-447  bp. The 
polymorphic RC-L1s had been genotyped in the gDNA 
of the individuals examined. Therefore, in those individu-
als who were heterozygous for the presence of the RC-L1, 
the empty site was also amplified to compare the meth-
ylation status of the allele lacking the insertion. The PCR 
products were separated using gel electrophoresis, and 
the intensities of the bands were measured using Image 
J software (the software of the transilluminator (Biorad 
Molecular Imager, Chemidoc XRS +) highlighted satu-
rated signals of PCR products to ensure the images used 
in downstream analysis were not including saturated sig-
nals). The relative intensity of the PCR products from the 
methylated and unmethylated fractions of DNA from the 
same individual were compared to determine the per-
centage which was methylated. A two-tailed student’s 
T-test was used to analyse the statistical differences 
between the proportion of the RC-L1s that were methyl-
ated between different tissues and disease states.
Results
Investigating a potential association of five specific, highly 
active polymorphic RC‑L1 loci with ALS
Seven genomic RC-L1 loci were selected from the litera-
ture due to their exceptionally high retrotransposition 
rate (89.4 to 150% of  L1RP) as determined in L1 retro-
transposition reporter assays in cell culture [11, 14, 42] 
or because they were shown to serve as highly active 
source elements in  vivo in the germline or in tumours 
[15, 17] (Table  1). The L1 in  vivo activity of individual 
RC-L1 source loci had been quantified by the mapping of 
3′ transduction events of de novo L1 insertions that were 
derived from these source loci (Table 1) in the germline 
[15] or in tumour tissues [17]. The seven RC-L1 loci were 
chosen as they were referred to as ‘hot’ or exceptionally 
active in at least one of the parameters outlined above. 
In Gardner et al. 38 RC-L1 loci were identified as gener-
ating germline 3′ transduction events and the three loci 
(L1_chr2_q24.1, L1_chr6_q24.1 and L1_chr1_p12) gave 
rise to more than half of these transductions (Table  1) 
[15]. In Tubio et al. the two ‘hot’ RC-L1_loci chr6_q24.1 
and L1_chr22_q12.1 together were responsible for more 
than a third of the somatic transduction events (Table 1) 
[17]. Finally Brouha et al. defined ‘hot’ L1s as those ele-
ments that demonstrated a third of the activity of a 
known highly active element  (L1RP)) in a cellular retro-
transposition assay and L1_chrX_p22.2, L1_chr6_p22.3 
and L1_chr8_q24.22 showed the three highest percentage 
activities of 82 elements tested [11]. With the exception 
of the two highly active non-reference RC-L1 insertions 
L1_chr2_q24.1 and L1_chr6_q24.1 (Table  1), which are 
polymorphic for their presence/absence and are not part 
of the reference genome, the remaining five RC-L1 loci 
are annotated in the hg19 reference genome, three of 
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which are also polymorphic for their presence/absence 
[11, 15].
The five polymorphic RC-L1 loci were genotyped, using 
PCR to amplify the RC-L1 5′ junctions if present and the 
empty site if the RC-L1 was absent, in healthy controls 
(minimum of 176) and SALS individuals (minimum of 
173) from the MNDA UK DNA bank cohort. Association 
analysis of each RC-L1 locus did not demonstrate any 
significant association with SALS (insertion allele fre-
quencies and p values are reported in Table 2). To extend 
this analysis further and increase the number of individu-
als genotyped without the need for PCR, tagging SNPs in 
the genomic region flanking the site of the L1 insertion 
were identified for each of the five polymorphic RC-L1 
insertions listed in Table 1. Both the SNP and RC-L1 gen-
otypes were available in a minimum 289 individuals and 
LD was calculated between the RC-L1 and their respec-
tive SNPs. All  r2 values were greater than 0.90 showing 
strong LD between the RC-L1s and their proxy SNPs and 
specific values are shown for each of the five polymor-
phic RC-L1s listed in Table 2. This enabled the presence/
absence of each RC-L1 in the UK samples from Project 
MinE to be determined from the genotype of their proxy 
SNP (Table  2). In this UK cohort there was no associa-
tion of any of the five individual polymorphic RC-L1 gen-
otypes with ALS using SNP genotypes as a proxy and p 
values are shown in Table 2.
The risk that polymorphic RC-L1s in the germline 
could contribute to disease may not be due to one 
individual RC-L1 insertion but a combination of mul-
tiple RC-L1 elements within the genome. Due to the 
presence or absence of the polymorphic RC-L1 inser-
tions, the total number of alleles across the five loci 
harbouring an RC-L1 insertion will vary between 
individuals. Therefore, for each individual, we deter-
mined the total number of alleles that contained an 
RC-L1 insertion at the five polymorphic loci listed in 
Table 1. A male could harbour between 0 and 9 and a 
female between 0 and 10 alleles with a RC-L1 insertion 
present at the five RC-L1 loci genotyped in this study. 
Using the genotypes of the proxy SNPs for each RC-L1 
locus in the Project MinE UK cohort the total number 
of present alleles per individual was determined for the 
five polymorphic RC-L1 loci (Table  1). In males, 1.7% 
of healthy controls and 1.8% of the individuals with 
ALS did not carry any of the five RC-L1 insertions in 
Table  1. In male controls and people with SALS, the 
greatest number of RC-L1 loci (out of those listed in 
Table 1) per genome was 6 and 7, respectively (Fig. 1a). 
In females 0.53% of healthy controls and 1% of people 
with ALS did not carry any of the five RC-L1 insertions 
presented in Table  1 and the greatest number of RC-
L1s at the five polymorphic loci per genome in both the 
controls and people with SALS was 8 (Fig. 1b). Logistic 
regression analysis in males and females revealed there 
was no association of the number of RC-L1s present 
at the 5 polymorphic loci analysed with disease status 
(males p = 0.90, females p = 0.64). For the RC-L1 loci 
investigated here, there was no increased burden of 
their presence in ALS genomes from 1320 individuals 
of the UK Project MinE cohort.
Table 2 Allele frequencies of polymorphic RC-L1s are similar using PCR or tagging SNPs to determine L1 genotype
Each polymorphic RC-L1 was genotyped using PCR and then expanded into the larger cohort of the UK Project MinE samples using tagging SNPs as a proxy for the L1 
genotype and each method demonstrated a similar insertion allele frequency (IAF). The RC-L1s were in strong LD with their respective tagging SNPs demonstrated by 
the  r2 values. There was no significant association of any of the RC-L1s with SALS by either genotyping method (chi-squared test). Number in brackets in columns IAF 
of L1 based on PCR and IAF of L1 based on SNP indicate the number of individuals per cohort
L1 (Tagging SNP) IAF of L1 based on PCR p value based 
on PCR genotypes





Controls (243) 0.30 0.67 0.95,0.98 Controls (386) 0.32 0.38
SALS (220) 0.29 SALS (1331) 0.30
L1_chr6_q24.1
(rs1150602)
Controls (494) 0.14 0.32 0.90,1.00 Controls (340) 0.17 0.36
SALS (445) 0.16 SALS (1178) 0.18
L1_chr6_p22.3
(rs6932875)
Controls (180) 0.14 0.39 0.90,0.97 Controls (357) 0.16 0.99
SALS (179) 0.12 SALS (1227) 0.15
L1_chr8_q24.22
(rs7844570)
Controls (176) 0.45 0.66 0.99,1.00 Controls (385) 0.46 0.34
SALS (177) 0.44 SALS (1330) 0.44
L1_chrX_p22.2
(rs6640825)
Female controls (114) 0.57 0.31 0.94,0.99 Female controls (233) 0.59 0.56
Female SALS (54) 0.51 Female SALS (509) 0.57
Male controls (64) 0.56 Male controls (139) 0.58
Male SALS (119) 0.55 Male SALS (740) 0.60
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Six selected RC‑L1 loci exhibit lower methylation levels 
of the L1 promoter region in the motor cortex of familial 
and sporadic ALS brains compared to control brains
gDNA samples isolated from motor cortex, cerebellum 
and blood from controls and people with sporadic or 
familial ALS (a total of nine individuals) were enriched 
for methylated gDNA fragments by pulling down meth-
ylated gDNA using MBD protein and thereby separat-
ing methylated from unmethylated gDNA fractions. The 
specific gDNA targets of interest were then amplified 
from both fractions by PCR in order to determine if the 
region of interest was enriched either in the methylated 
or unmethylated gDNA fraction. As an internal control, 
the CpG island of the imprinted locus small nuclear rib-
onucleoprotein polypeptide N (SNRPN) was amplified 
in each gDNA sample to ensure successful isolation of 
methylated and unmethylated DNA fractions as only one 
of the two SNRPN alleles is methylated. Amplifying this 
CpG island also demonstrated on average an equal rep-
resentation of the methylated and unmethylated allele 
in the respective gDNA fractions. The average relative 
methylation of the CpG island of the SNRPN locus in cer-
ebellum, motor cortex and blood comprised of 50%, 48% 
and 55%, respectively (Fig. 2a–c).
Six out of the seven RC-L1s shortlisted in Table  1 
(L1_chr1_p12, L1_chr22_q12.1, L1_chr6_q24.1, L1_
chrX_p22.2, L1_chr6_p22.3 and L1_chr8_q24.22) were 
analysed for their relative levels in methylated and 
unmethylated gDNA fractions of DNA. The RC-L1 locus 
L1_chr2.q24.1 had to be excluded from our analysis, 
Fig. 1 Burden of five specific RC‑L1 loci in healthy controls and individuals with SALS. a Percentage of male individuals harbouring different 
numbers of specific RC‑L1 present alleles of the polymorphic L1 loci listed in Table 1 was determined by using tagging SNPs as a proxy for the L1 
genotype in controls and SALS patients. In males, it is possible to have up to 9 alleles with a RC‑L1 present of the 5 loci genotyped. b Percentage 
of female individuals harbouring different numbers of RC‑L1 present alleles of the polymorphic L1 loci listed in Table 1 was determined by using 
tagging SNPs as a proxy for L1 genotype in controls and SALS. In females, it is possible to have up to 10 alleles with a RC‑L1 present of the 5 loci 
genotyped. Two‑sample test for equality of proportions to compare number of RC‑L1 between cases and controls. Male‑Controls n = 117, SALS 
n = 616, Female—Controls n = 187, SALS n = 400
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because it was not possible to generate the RC-L1 locus 
specific 985-bp PCR product in the sheared gDNA used 
as input in MBD assay. People heterozygous for the pres-
ence of a particular RC-L1 insertion allowed for the 
simultaneous comparison of this region of gDNA with 
and without the RC-L1 present to determine the effect 
of the 5′ UTR of the L1 on methylation status. At the 14 
heterozygous RC-L1 loci analysed, the allele lacking the 
RC-L1 insertion had a significantly lower level of meth-
ylation compared to the allele harbouring the RC-L1 
insertion (average relative methylation of empty site and 
RC-L1 5′end equals 2% and 79%, respectively; p < 0.001) 
across all types of tissue (cerebellum, motor cortex and 
blood) (Fig.  2d–f). Figure  2e shows presence/absence 
PCR analyses of the genomic RC-L1 loci L1_chr6_q24.1 
and L1_chrX_p22.2 with the empty site being enriched in 
the unmethylated gDNA fractions from both blood and 
motor cortex relative to the 5′ junctions of RC-L1 loci 
that are enriched in the methylated fractions. This com-
parison confirmed that the differential methylation is 
associated with the insertion of the RC-L1, which would 
be expected due to the introduction of the L1 CpG island, 
rather than the nature of the flanking gDNA.
To determine if the methylation state of the RC-L1s 
was tissue dependent, we compared the percentage of the 
RC-L1 5′ junction in the methylated fraction of gDNA 
Fig. 2 Analysis of methylation status of imprinted SNRPN locus and heterozygous RC‑L1 insertions. a Schematic showing location of binding 
sites of primers in the SNRPN locus used to PCR amplify its CpG island as an internal control for the successful enrichment of methylated and 
unmethylated gDNA fractions. Blue box –exon. b Example gel image of PCR product (263 bp) amplified from SNRPN CpG island in methylated 
and unmethylated fractions of DNA from all three tissues. (Cer cerebellum, MCX motor cortex, M methylated fraction of DNA, U unmethylated 
fraction of DNA). c Box‑Whisker plot demonstrating methylation status of the CpG island of the imprinted SNRPN locus in cerebellum, motor 
cortex and blood of 9 individuals. Methylation status was determined by comparing the band intensity of the PCR product in the methylated and 
unmethylated fractions of gDNA. The average methylation of the CpG island of the SNRPN locus in cerebellum, motor cortex and blood comprises 
55%, 48% and 55%, respectively. Cerebellum, n = 6 (controls = 2, FALS = 2, SALS = 2); MCX, n = 9 (controls = 2, FALS = 2, SALS = 5); blood, n = 3 
(SALS = 3). d Schematic showing the position of binding sites of primers used to amplify the genomic 5′ junction of the selected full length RC‑L1 
loci when present (filled site) and the empty site when the respective RC‑L1 is absent. The L1 5′UTR‑specifc primer binds position 223–206 of the 
L1.3 reference sequence TSD, target site duplication; UTR, untranslated region; ORF1 and ORF2, open reading frame 1 and 2;  An, polyA stretch; e 
PCR analysis of 5′ junctions of RC‑L1 loci L1‑chr6‑q24.1 and L1‑chrX‑p22.2 and the empty sites of heterozygous carriers in the methylated and 
unmethylated gDNA fractions from blood and motor cortex of same individual. f The 5′ junction of the RC‑L1s is enriched in the methylated fraction 
of DNA, while the empty sites (absent allele) lack any meaningful methylation in heterozygous carriers. Average methylation status of 5′ junctions 
RC‑L1 loci and empty sites comprises 79% and 2%, respectively (14 heterozygous RC‑L1 loci). Two‑tailed t‑test *** p < 0.001 X = mean
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from the cerebellum, motor cortex and blood of all indi-
viduals (controls, FALS and SALS). While 5′ junctions of 
RC-L1 loci are on average methylated to the same degree 
in cerebellum and motor cortex, there is a significant 
difference in the methylation status between the highly 
methylated RC-L1 5′ junction in blood relative to the less 
efficiently methylated L1 promoter regions in neuronal 
tissues tested (cerebellum—75%, motor cortex—72% and 
blood—91%) (Fig. 3a and Additional file 3a). When com-
paring the average methylation status of 5′ junctions of 
the six selected RC-L1 loci in the cerebellum of 2 control 
brains with those of 2 FALS and 2 SALS brains (Fig. 3b) 
there was no significant difference (controls—75%, 
FALS—82%, SALS—68%). Although a higher proportion 
of RC-L1 5′ junctions was methylated in people with 
FALS than in people with SALS or controls. However, 
in the motor cortex of people with FALS and SALS, the 
average percentage of the RC-L1 5′ junction in the meth-
ylated fraction was significantly lower than compared to 
the controls (controls—96%, FALS—63%, SALS—70%) 
(Fig. 3c and Additional file 3b). In the controls 91–100% 
of the PCR products obtained from 5′ junctions of the 
selected RC-L1 loci were derived from the methylated 
fraction depending on the locus, while contrarily 30–84% 
in FALS and 32–100% in SALS were derived from the 
methylated fraction. This indicates that in the motor cor-
tex of people with FALS and SALS, the 5′ junctions of the 
selected RC-L1 loci exhibit significantly lower levels of 
Fig. 3 Comparison of the methylation of six selected RC‑L1 loci by tissue and affected status. a Box‑Whisker plots indicate the methylation status 
of the 5′ junctions of six RC‑L1 loci (L1_chr1_p12, L1_chr22_q12.1, L1_chr6_q24.1, L1_chrX_p22.2, L1_chr6_p22.3 and L1_chr8_q24.22; see Table 1) 
in the cerebellum (Cer), motor cortex (MCX) and blood. The average methylation status of 5′ junctions of the RC‑L1 loci in cerebellum, motor cortex 
and blood constituted 75%, 72%, and 91%, respectively. Number of RC‑L1 5′ junctions analysed – Cer n = 22, MCX n = 33, blood n = 11 across 9 
individuals (controls = 2, FALS = 2, SALS = 5). b Box‑Whisker plots presenting the methylation status of the 5′ junctions of the six RC‑L1 loci (see 
above) in the cerebellum of control individuals (n = 2), and FALS (n = 2) and SALS (n = 2) patients. The average methylation status of the 5′ junctions 
of the RC‑L1 loci in control individuals, FALS and SALS patients amounted to 75%, 82% and 68%, respectively. 22 RC‑L1 5′ junctions were analysed in 
the cerebella (controls n = 7, FALS n = 8, SALS n = 7). c Box‑Whisker Plots presenting the methylation status of the 5′ junctions of the six RC‑L1 loci 
(see above) in the motor cortex of control individuals (n = 2), and FALS (n = 2) and SALS (n = 5) patients. The average methylation status of the 5′ 
junctions of the RC‑L1 loci in control individuals, FALS and SALS patients amounted to 96%, 63% and 70%, respectively. 33 RC‑L1 5′ junctions were 
analysed in the motor cortices (controls n = 7, FALS n = 8, SALS n = 18). Two‑tailed t‑test ** p < 0.01, *** p < 0.001 X = mean
Page 9 of 12Savage et al. Mol Brain          (2020) 13:154  
CpG methylation on average compared to healthy con-
trols (Fig.  3c). Therefore, we set up the hypothesis that 
the expression of these RC-L1 loci may be increased in 
the motor cortex of people with SALS or FALS. To con-
firm this hypothesis, future work has to investigate both 
expression of functional L1 loci in the motor cortex of 
people with FALS and SALS relative to healthy controls 
and potential L1 retrotransposition events that would be 
expected to occur as a consequence of transcriptional 
upregulation of RC-L1 loci in this specific tissue. Due to 
the limited amounts of available patient material, it was 
not possible to include such experiments in our pre-
sented study.
Discussion 
The human genome harbours two sets of RC-L1 loci. 
There is one set that all individual genomes have in com-
mon, and the other set whose members are polymor-
phic for their presence or absence. Therefore, numbers, 
genomic locations and mutagenic potential of RC-L1s 
differ between individuals. Our study focussed on seven 
highly active RC-L1 loci (including five polymorphic L1 
elements and two L1 insertions fixed in the reference 
genome) of the 80 functional reference L1 insertions 
[11] and ~ 100 functional non-reference L1 loci were 
reported to date [14, 15, 17, 48]. The five polymorphic 
RC-L1 loci were genotyped by PCR amplification ini-
tially (between 351 and 939 individuals involved depend-
ing on the RC-L1 locus analysed) and tagging SNPs were 
used to increase the number of individuals analysed 
(between 1518 and 1717 individuals depending on the 
SNPs passing quality control) who were taken from the 
UK MNDA DNA bank cohort and the UK samples from 
Project MinE. We determined that the five polymorphic 
RC-L1s were not associated with SALS individually and 
an increasing burden of these five specific RC-L1 loci did 
not affect the likelihood of having the disease (Table  2 
and Fig. 1).
An essential prerequisite for L1 mobilisation is the 
expression of functional L1 mRNA and the L1-encoded 
protein machinery including ORF1p and ORF2p from 
genomic RC-L1 elements. L1 expression is regulated by 
methylation of a CpG island located in the L1 5′UTR 
between pos. 30 and pos. 450 of an intact L1 element 
and this is mediated by a highly conserved Yin Yang 
1 transcription factor binding site [19, 20, 49, 50]. We 
assessed the methylation status of the CpG-island of the 
5′ UTR of six specific RC-L1 loci in gDNA from motor 
cortex and matching cerebellum or blood isolated from 
those individuals with or without disease. On aver-
age, the level of methylation was significantly lower in 
the two brain regions analysed when compared to the 
blood (Fig.  3a), which is consistent with the established 
fact that L1s have the ability to retrotranspose in neu-
ronal cells. Our PCR analyses identified a significantly 
higher level of methylation of the promoter region of 
the listed six RC-L1 loci in the motor cortex (the region 
of the brain primarily affected by ALS) of control brains 
compared to those from people with either sporadic or 
familial ALS (Fig. 3c). However, this study was limited to 
a small number of available samples from two controls, 
two people with FALS and five with SALS therefore fur-
ther work would be needed to establish if this reduced 
methylation is a reoccurring feature of disease or natu-
ral variation in the level of methylation of these elements 
across different people. Reduced methylation of RC-L1 
promoters has been shown to lead to an increase in the 
expression of functional L1 gene products and L1 retro-
transposition [20, 51, 52]. Consistently, patients with Rett 
Syndrome carrying mutations in MeCP2, which estab-
lishes repression by DNA methylation through binding 
to the methylated gDNA, have increased susceptibility 
for L1 retrotransposition [53]. Activation of L1 retro-
transposons confer genomic and cellular instability as L1 
insertions can disrupt coding regions and modify epige-
netic and post-transcriptional regulation of gene expres-
sion. Destabilisation of the genome can be caused by an 
increase in endogenous L1 retrotransposition frequency 
and by L1-encoded endonucleolytic activity of ORF2p, 
which can cause genomic DNA damage that could also 
negatively affect health and survival of the cell [4, 6, 54]. 
The high metabolic activity of neurons and their inabil-
ity to use replication-coupled DNA repair mechanism 
makes them vulnerable to DNA damage, which was 
reported to occur in neurodegenerative disorders includ-
ing ALS [55, 56]. In addition, a Drosophila model of ALS 
demonstrated the de-repression of transposable elements 
(including members of the L1 superfamily) that were 
involved in DNA damage-induced cell death of neurons 
[37]. It has also been suggested that the expression of 
functional L1 proteins could increase the L1 DNA con-
tent of a cell without retrotransposition occurring due 
to the extrachromosomal accumulation of L1 cDNA that 
had not integrated into the nuclear genome due to failed 
or incomplete target primed reverse transcription [29]. 
This could potentially have damaging effects by triggering 
an immune response or tying up host factors involved in 
regulating cellular processes [29, 57–60]. A recent study 
of ALS-FTD brains, using a qPCR assay that did not dis-
tinguish if changes in L1 copy number is due to success-
ful retrotransposition or any other mechanism raising 
the number of L1 copies in gDNA preparations, showed 
an increase in the L1 copy numbers in TDP-43 negative 
nuclei [41]. Other neurological diseases, including Rett 
Syndrome and ataxia telangiectasia, have also been asso-
ciated with elevated L1 DNA content [53, 61].
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ALS is a complex disorder involving both genetic 
and environmental risk factors for developing the dis-
ease with multiple steps in the molecular processes 
that result in ALS [62]. Our study of a small number of 
highly active RC-L1s did not identify an association of 
their genotype with ALS. However, there are approxi-
mately 165 potential alternative RC-L1 loci across the 
human genome and therefore further studies will be 
required to fully explore their potential to be part of 
the genetic landscape that predisposes an individual 
to ALS. Applying bioinformatics tools such as Mobile 
Element Locator Tool [15], for genotyping both ref-
erence and non-reference L1 insertions using whole 
genome sequencing data would enable a genome wide 
analysis of all known RC-L1 loci. This would allow for a 
more comprehensive analysis of the potential contribu-
tion of RC-L1 loci to the genetic risk of ALS in future 
studies. However, our pilot study did demonstrate 
that the methylation of CpG-islands of the 5′UTRs of 
the selected RC-L1 loci is reduced in the motor cor-
tex of those people with ALS relative to healthy indi-
viduals in the small number of samples analysed here. 
Changes to RC-L1 regulation could be involved in 
downstream molecular events of the disease process 
influencing cellular function through various mecha-
nisms that include direct effects of the RC-L1 mRNA 
and proteins such as mobilisation or the through their 
modulation of expression of neighbouring genes. Our 
study has highlighted RC-L1s as important genetic ele-
ments for further investigation in ALS. Further studies 
to expand on these findings to help decipher the role 
of the elements should include addressing the question 
of the level of mobilisation, a genome wide approach 
to their variation and methylation status, determining 
mRNA expression levels from RC-L1s and the effect 
of the presence or absence of these insertions on gene 
expression.
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